Articles tagged with Drug Design
A study emulated a clinical trial using real-world UK healthcare data to explore treatment effects in patients with atrial fibrillation. The method found similar outcomes between apixaban and warfarin, but with differences linked to ethnicity and medication use.
Researchers characterized bemnifosbuvir's activation cascade at atomic resolution, paving the way for the design of new broad-spectrum antiviral drugs. The study provides insights into the mechanism of action of this antiviral compound, which could lead to more effective treatments against various viral infections.
A new study published in the Stroke journal found that people with brain aneurysms are at higher risk of developing mental health conditions, including anxiety. The study, which analyzed data from over 85,000 people, found that younger adults were particularly vulnerable to this increased risk.
Researchers at Uppsala University used AI to predict the three-dimensional structure of a receptor, identifying molecules that bind to it with higher accuracy than traditional methods. This breakthrough accelerates the development of new drugs for mental health disorders such as schizophrenia and depression.
A deadly marine cone snail's venom contains a toxin that interacts with human cells in a specific manner, regulating blood sugar levels and hormone balance. This discovery may lead to the design of more effective drugs for treating diabetes and endocrine disorders.
The new battery can capture oxygen from air and use it to oxidize zinc, creating a current of up to 1 volt. It powers an actuator, memristor, clock circuit, and sensors, making it ideal for robotics and medical applications.
A new study found that job strain and effort-reward imbalance at work increase the risk of developing atrial fibrillation, an abnormal heart rhythm. The research suggests that recognizing and addressing psychosocial stressors at work can foster healthy environments.
Researchers developed a novel EIT-EVA PCB sensor for non-invasive assessment of drug inhibition on ion channels. The system enables real-time monitoring of ion flow changes in response to drug exposure, offering a faster and more efficient alternative to traditional methods.
Researchers designed a molecule, MTX-531, that impairs signaling drivers of cancer therapy resistance. In mouse models, MTX-531 led to tumor regressions in multiple head and neck cancers, showing a favorable toxicity profile.
Scientists improve stability and bioavailability of mRNA nanocarriers using triphenylphosphonium, leading to increased protein production in tumor tissues. The TPP-based system also shows higher mRNA levels in blood after 30 minutes compared to amine-based micelles.
Studies published in Crystal Growth & Design highlight the suite's ability to visualize and quantify chemical and topological information from crystallographic data. This approach can reduce trial-and-error methods, providing data-driven guidance for formulators and particle engineers.
Researchers at the University of Cambridge have developed an atlas of proteins that reveals how they behave inside human cells. The tool allows for the identification of new proteins involved in important bodily functions, including fat distribution and protein creation.
Researchers develop a method that fuses AlphaFold's strengths with computer simulations based on physics laws to predict protein structures, enabling faster drug development. The approach filters down initial hypotheses to a more manageable set of structures, increasing the effectiveness of pharmaceuticals.
Researchers describe a new concept for an immune response against cancer and aging using senescent cell-derived vaccines. The vaccines aim to stimulate the immune system against cancer cells and slow down or reverse aging-related diseases.
Scientists have identified a mechanism that enables enzymes to communicate and produce organic molecules with disease-fighting properties. This breakthrough could aid in the discovery of new drugs by allowing researchers to design or modify enzymes to create novel natural products.
Researchers have made a breakthrough in understanding the GIP hormone's role in regulating insulin levels and weight loss. The study, involving over 500,000 individuals, found that inhibiting the GIP receptor may result in weight loss, while activating it without arresting its signal is crucial.
Dr. Alice Walker will investigate the design of fluorescent protein sensors using computer simulations, which may aid in tracking diseases and monitoring treatment effectiveness in living cells and organisms. The five-year $690,816 grant also supports undergraduate research opportunities for WSU students.
The researchers created soft robots equipped with electronic skins and artificial muscles to sense their surroundings and adapt in real-time. These robots can perform various tasks, such as monitoring internal conditions, providing treatments, and delivering drugs over an extended period.
Researchers highlight strategies for improving agriculture with nanotechnology, including targeted delivery of pesticides and herbicides, and digital twin simulations. These approaches aim to reduce environmental pollution and increase crop resilience.
Researchers at The Wistar Institute have developed a new, long-lasting antibody treatment called Persistent Multivalent T Cell Engager (CA9-PMTE) that targets clear cell renal cell carcinoma. This innovative therapy has shown promise in pre-clinical models and could potentially be used to treat other difficult-to-treat cancers.
Cleveland Clinic and IBM researchers develop a hybrid framework combining quantum and classical computing methods for protein structure prediction. This approach overcomes limitations of current classical methods and demonstrates improved accuracy in predicting protein structures.
Researchers have designed a method to 'cloak' proteins for targeted delivery into cells, utilizing lipid nanoparticles. The cloaked proteins can be captured by the nanoparticles and exert their therapeutic effect once inside the cell. This approach shows promise for repurposing antibodies and other proteins for cancer treatment.
The study highlights the importance of protease-activated receptors (PARs) in cancer growth and development, with PH-binding motifs identified as a key platform for drug design. The researchers suggest that targeting PARs could provide an alternative to current oncogenic pathways.
Scientists have discovered the transporters responsible for delivering essential nutrients choline and ethanolamine to human cells. The study sheds light on the atomic structure of these transporters and their role in distributing micronutrients throughout the body, providing a foundation for new therapeutic approaches.
Researchers found no significant 'participation effect' in cancer trials, contrary to common belief among patients and healthcare providers. The study's results provide reassurance that not enrolling in a trial doesn't disadvantage a patient's survival outcomes.
A phase 3 trial found that pamrevlumab did not significantly improve lung function in patients with idiopathic pulmonary fibrosis. The study's results underscore the need for effective treatments to slow disease progression and improve patient outcomes.
Nach0 was trained on diverse tasks, including natural language understanding, synthetic route prediction, and molecular generation. The model performed well on molecular tasks using molecular data and outperformed ChatGPT, making it a significant step toward unlocking the full potential of LLMs for drug discovery.
Researchers have developed a synthesis method for introducing difluoromethyl groups into pyridines, a promising approach for new drugs and agrochemicals. The method allows precise introduction of the group at specific sites, overcoming a long-standing challenge in the chemistry field.
Researchers have discovered new binding sites for medications in proteins by heating them to body temperature, revealing previously unknown structures. This breakthrough could lead to the development of more effective drugs for various health conditions, including stroke, heart disease, and diabetes.
Insilico Medicine's lead compound demonstrates strong enzymatic activity, selectivity, and favorable ADME properties, as well as antitumor activity in various animal models. The company's generative AI-powered platform generated over 3,600 candidate molecules before identifying the promising lead compound.
Researchers at Insilico Medicine developed COSMIC, a new framework for molecular conformation space modeling that provides accurate insights into molecule positioning and activity. This enables faster and more efficient drug design decisions.
Researchers at Gladstone Institutes have identified a blood coagulation protein, fibrin, as the culprit behind toxic inflammation and neuron loss after a major head injury. This finding can inform new treatment strategies for traumatic brain injuries, which often lead to dementia, depression, and difficulty concentrating.
Researchers at University of Texas M. D. Anderson Cancer Center have developed a new method for developing immunotherapy drugs using engineered peptides. The approach improved tumor control and prolonged survival in preclinical models of breast cancer.
Researchers from the University of Cambridge used AI to identify compounds that block alpha-synuclein aggregation, a key step in treating Parkinson's disease. This breakthrough could lead to faster development of new treatments for the condition, which affects over six million people worldwide.
Researchers at Insilico Medicine have identified a new class of Polθ inhibitors featuring central scaffolding rings, designed using Chemistry42, with significant enzymatic and cellular potency. The discovery showcases the potential of AI in medicinal chemistry for precise molecular modifications.
Researchers have developed a new treatment that uses tailored doses of anti-cancer drugs released directly into the surgical cavity to treat liver cancer. The approach has shown promise in reducing recurrence rates and minimizing chemotherapy side effects, with potential applications for other types of cancer.
A new statistical-modeling workflow can quickly identify molecular structures of products formed by chemical reactions, accelerating drug discovery and synthetic chemistry. The workflow also enables the analysis of unpurified reaction mixtures, reducing time spent on purification and characterization.
Researchers at Insilico Medicine developed QFASG, a quantum-assisted algorithm generating novel small-molecule structures from fragments. The tool successfully designed inhibitors for cancer-related proteins, showcasing its potential in accelerating drug discovery and development.
Researchers found that nontraditional stroke risk factors like migraines are as important as traditional risk factors like high blood pressure for adults younger than ages 35-45. The association between stroke and nontraditional stroke risk factors was stronger in adults younger than 35 years old.
Researchers have developed a new, synthetic lung surfactant that mimics the functionality of animal-derived formulations. The surfactant has shown promise in reducing surface tension and may offer a cheaper alternative to Infasurf.
Researchers have developed an AI model called SyntheMol that can design new antibiotics against deadly bacteria like Acinetobacter baumannii. The model identified six potent antibacterial compounds with non-toxic properties, offering a potential solution to the global crisis of antibiotic resistance.
Researchers have developed nanoparticles that can inactivate multiple strains of the SARS-CoV-2 virus by targeting its twist in the spike protein. These particles show promise as a complementary treatment for COVID-19 when vaccines and other treatments are ineffective, particularly against vulnerable populations.
A Stanford University research team has developed a potential new anti-coronavirus drug that binds more tightly and durably than current treatments like Paxlovid. The compound, ML2006a4, performed well in preclinical experiments against SARS-CoV-2 variants that have evolved resistance to Paxlovid.
Researchers have demonstrated novel proteins that can efficiently reach intramembrane targets using a customized computer-based approach. The study yields a general computational process for streamlining protein design aimed at intramembrane targets, opening up possibilities for therapeutic applications and understanding signaling mech...
Researchers used generative AI to design a lead molecule for treating fibrosis, a biological process associated with aging. The compound, INS018_055, demonstrated significant efficacy in preclinical studies and showed promising results in clinical trials, accelerating drug discovery and providing new therapeutic options.
A novel antibody constant region variant (REW) extends plasma half-life and improves biodistribution, allowing for both invasive and non-invasive delivery. The REW technology also enhances the complement system, providing enhanced ability to kill cancer cells and bacteria.
PandaOmics uses advanced AI algorithms to process vast quantities of diverse data, performing gene and pathway analysis and target predictions. The platform has been extensively validated in multiple therapeutic areas, including oncology, inflammation, and immunology.
University of North Carolina at Chapel Hill researchers have developed a new drug delivery platform that harnesses helical amyloid fibers designed to untwist and release drugs in response to body temperatures. This discovery could be useful in treatment to reverse Alzheimer’s Disease impact by degrading amyloid plaques.
Researchers have developed a new class of antibiotics that can overcome drug-resistant bacteria by targeting the physical and functional integrity of the bacterial cell wall. This could be a game-changer in treating infections, particularly those caused by resistant strains.
Scientists from IOCB Prague have developed a universal and accurate new computational method to predict how proteins interact with drugs. The SQM2.20 scoring function yields DFT-quality predictions in minutes, significantly accelerating drug discovery.
Scientists have developed a cage-like molecule to trap sulfate in water, which could help control its concentration in health, industry, and environmental management. The molecular trap can be prepared inexpensively from off-the-shelf chemicals and has potential applications in medicine, such as treating cystic fibrosis.
Scientists at the University of California, Riverside, have identified 898 RNA-dependent proteins in the deadliest human malaria parasite, Plasmodium falciparum. These findings could lead to novel therapeutic targets against malaria and highlight the importance of RNAs in biological pathways in the parasite.
Researchers develop nanovector nanogels that selectively target glial cells involved in spinal cord injury inflammation, reducing damage and improving recovery. The treatment demonstrates potential for modulating glial cells in neurodegenerative diseases like Alzheimer's.
Chemical simulations can be sped up by resetting them, a new study from Tel Aviv University found. This technique, called stochastic resetting, overcomes the timescale problem, allowing for more accurate predictions of slow processes.
Researchers have created a genAI model called 'drugAI' that can generate unique molecular structures for potential drugs with high binding affinity and efficacy. The model outperforms traditional methods in terms of speed and cost, opening up new possibilities for disease treatment.
A new study published in the American Heart Association journal Hypertension found that tirzepatide significantly lowered systolic blood pressure levels in nearly 500 adults with obesity. The results suggest treating obesity with this weight loss medication may be an effective strategy for preventing or treating high blood pressure.
Researchers discovered that reducing cholesterol levels in mice with advanced atherosclerosis leads to a decrease in the number of smooth muscle-derived cells causing plaque growth, while preserving stabilizing cell types. This finding opens up new opportunities for targeted therapies.
GIST researchers develop tunable optical properties in nanostructures, enabling applications in wound healing, drug delivery, and secure verification. A clock-inspired design featuring magnesium nano-rotamers demonstrates programmable polarization-resolved coloration.
Researchers discover antibody-dependent enhancement of toxicity (ADET), a phenomenon where antibodies can amplify venom's potency. The breakthrough contributes to expediting the development of a new generation of antivenom, potentially saving millions from snakebites yearly.
Researchers developed a platform combining automated experiments with AI to predict chemical reactivity, greatly accelerating the design process for new drugs. A machine learning model predicts where molecules will react and how reaction sites vary under different conditions, enabling precise tweaks to complex molecules.